Home  /  Resource Library  /  Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis

Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis

Study examined the cost effectiveness of adding rituximab to chemotherapy.